Loading...

          

XIIth International Myeloma Workshop
Loading...
Educational Materials  »    PDF - 3.665 kB

Table Of Contents (Spis treści)


Myeloma Molecular Pathways/Cytogenics
Rafael Fonseca, MD
Mayo Clinic, Scottsdale, AZ
Role Of FISH In Myeloma Risk Stratification
Hervé Avet-Loiseau, MD, PhD
Hematology Laboratory, University Hospital, and INSERM U892, Nantes, France
Genetic Changes In Myeloma: Prognostic Implications
Johannes Drach - johannes.drach@meduniwien.ac.at
Medical University of Vienna, Department of Medicine I, Clinical Division of Oncology,Vienna, Austria
Redefining Risk Using Cytogenetic Changes
Professor Gareth Morgan
The Institute of Cancer Research, London, United Kingdom
High-Throughput Molecular Profiling; Insights into Myeloma Pathogenesis And Clinical Outcome
John D. Shaughnessy, Jr., Bart Barlogie
University of Arkansas for Medical Sciences, Little Rock, AR
New Insights into The Molecular Basis Of MM Pathogenesis And Prognosis
Myeloma - Signaling Pathways
Teru Hideshima, Hiroshi Ikeda, Constantine Mitsiades, Dharminder Chauhan, James E. Bradner, Nikhil C. Munshi, Paul G. Richardson, Kenneth C. Anderson
Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA
Modulation Of Signaling Cascades By Inhibitors of Histone Deacetylase And Akt.
Constantine S. Mitsiades - constantine_mitsiades@dfci.harvard.edu, Douglas W. McMillin, Jake Delmore, Joseph Negri, Steffen Klippel, Melissa Ooi, Nikhil C. Munshi, Paul G. Richardson, Kenneth C. Anderson
Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston MA 02115, USA
Molecular Pathways Induced By Tumor – Microenvironment Interactions In Myeloma; Regulatory Role Of Heat Shock Proteins
A. K. Stewart, R. E. Tiedemann, Y. Zhu
Mayo Clinic, Scottsdale, AZ
RNAi Vulnerability Map in Multiple Myeloma
P. Leif Bergsagel, J. Jonathan Keats, Marta Chesi, W. Michael Kuehl
Mayo Clinic, Scottsdale, AZ
Targeting NFkß Signaling In Multiple Myeloma
Anne Catherine Sprynski1, Dirk Hose2,3, Jérôme Moreaux1,4, Thierry Reme1,4, Michel Jourdan1, Philippe Bourin5,
Jil Corre5, Bart Barlogie6, John Shaughnessy6, Jean François Rossi1,4,7, Golsdchmidt Harmut2,3, Bernard Klein1,4,7
1. INSERM, U847, Montpellier, F34197 France
2. Medizinische Klinik V, Universitätsklinikum Heidelberg, INF410, Germany
3. Nationales Centrum für Tumorerkrankungen, INF350, D69115 Heidelberg, Germany
4. CHU Montpellier, Institute of Research in Biotherapy, F34285 France
5. EFS, Toulouse, France
6. Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
7. Université MONTPELLIER1, UFR Medecine, Montpellier, France
Cytokine Pathways In Myeloma Growth And Survival
Myeloma Immune and Antibody Targets
Qing Yi, MD, PhD
Department of Lymphoma and Myeloma, Division of Cancer Medicine, and the Center for Cancer Immunology Research, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
Novel Antigenic Targets For Immunotherapy In Myeloma
Diane F. Jelinek, Ph.D.
Mayo Clinic, Rochester, MN USA
Growth And Survival Signals In Myeloma: Roles For Baff and April
Madhav V. Dhodapkar, MD
Yale University, New Haven, CT, USA
Immune Microenvironment In Myeloma Pathobiology
Yu-Tzu Tai, Mariateresa Fulciniti, Pierfancesco Tassone, Paola Neri, Constantine Mitsiades, Teru Hideshima, Dharminder Chauhan, Paul Richardson, Kenneth C. Anderson, Nikhil C. Munshi
Dana-Farber Cancer Institute, Boston VA Healthcare System, Harvard Medical School, Boston, MA
Monoclonal Antibody - Based Therapies in Human Multiple Myeloma
Surinder S. Sahota1, Niklas Zojer2, Gavin Babbage1, Debora Joseph-Pietras1, Nicola Weston-Bell1, Bernard Klein5, Karin Vanderkerken3, Pieter Sonneveld4, Karen Pulford6, Jason Rice1, Natalia Savelyeva1, Christian Ottensmeier1
1. Cancer Sciences Division, School of Medicine, University of Southampton, UK
2. Center for Oncology and Hematology, Wilhelminenspital, Vienna, Austria
3. Department Hematology and Immunology, Vrije Universiteit Brussel, Belgium
4. Department Hematology, Erasmus MC and Erasmus University, Rotterdam, The Netherlands
5. Institute of Research in Biotherapy, INSERM Unit 847, CHU Montpellier, Hopital Saint Eloi, Montpellier, France
6. Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, University of Oxford, UK
Defining Multiple Myeloma As A Target For DNA Fusion Gene Vaccines
Myeloma Microenvironment
G. David Roodman1,2, Yuko Hiruma1, Noriyoshi Kurihara1
1. University of Pittsburgh, Medicine/Hem-Onc, Pittsburgh, PA
2. VA Pittsburgh Healthcare System, Medicine/Hem-Onc, Pittsburgh, PA, USA
p62 – A Potential Target For Blocking Microenvironmental Support of Myeloma
Irene M. Ghobrial MD, Aldo Roccaro MD PhD, Abdel Kareem Azab PhD, Judith Runnels PhD, Xavier Leleu MD PhD
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
Trafficking Of MM Cells: What Regulates Homing, Adhesion, And Mobilization Of Multiple Myeloma To And From The Bone Marrow Niches
Angelo Vacca1 - a.vacca@dimo.uniba.it, Roberto Ria1, Domenico Ribatti2, Franco Dammacco1
1. Department of Internal Medicine and Clinical Oncology
2. Department of Human Anatomy, Histology and Embryology, University of Bari Medical School, I70124 Bari, Italy
Genes And Proteins Of Myeloma Endothelial Cells To Search Specific Targets Of The Tumor Vasculature
Karin Vanderkerken, Elke De Bruyne, Sarah Deleu, Miguel Lemaire, Els Van Valckenborgh, Ivan Van Riet,
Eline Menu, Isabelle Vande Broek, Tomas Bos, Ben Van Camp
Part of this work was supported by a grant from the European Commission FP6 to MSCNET
Vrije Universiteit Brussel (VUB), Department Hematology and Immunology, Laarbeeklaan 103, B1090 Brussels, Belgium
Epigenetic Regulation Of Multiple Myeloma Within Its Bone Marrow Microenvironment
Evangelos Terpos, Dimitrios Christoulas, Efstathios Kastritis, Magda Migkou, Maria Gavriatopoulou,
Meletios-Athanassios Dimopoulos
Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
Novel Anti-Myeloma Agents And Bone Metabolism: Implications Into The Management Of Myeloma Bone Disease
Phase III Studies
Philippe Moreau
University Hospital, Nantes, France
Phase III Studies Published By the IFM (Intergroupe Francophone Du Myélome)
S. Lonial, S. Giralt, B. Durie, B. Barlogie, E. Stadtmauer, K. Anderson, V. Rajkumar
US Cooperative Group Trials
Donna E. Reece, MD
Princess Margaret Hospital, University Health Network, Toronto, Canada
Canadian Collaborative Trials
Boccadoro M, Palumbo A, Cavo M, Di Raimondo F, Bringhen S, Magarotto V, Larocca A, Mateos MV, Lahuerta JJ, Cibeira MT, Martínez J, Rosinol L, Bladé J, San Miguel J
GIMEMA (Italian Group for Adult Hematologic Diseases/Multiple Myeloma WorkingParty)
PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatía Maligna)
The activity of Spanish and Italian Myeloma Groups
P. Sonneveld
Erasmus MC, Rotterdam, The Netherlands
Phase III Studies by Northern European Groups in Multiple Myeloma
Phase II Studies
Paul Richardson MD1, Jacob Laubach MD1, Robert Schlossman MD1, Irene Ghobrial MD1, Teru Hideshima MD1, Constantine Mitsiades MD PhD1, Dharminder Chauhan PhD1, Noopur Raje MD1,2, Nikhil Munshi MD1,
Kenneth C. Anderson MD1
1. Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute
2. Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
Novel Combination Therapies For The Treatment Of Relapsed/Refractory Multiple Myeloma:
Current Phase I/II Combinations
Palumbo Antonio1 - appalumbo@yahoo.com, Bringhen Sara1, Gay Francesca1, La Rocca Alessandra1,
Cavallo Federica1, Offidani Massimo2, Di Raimondo Francesco3, Boccadoro Mario1
1. Divisione di Ematologia Dell’Universita di Torino, Azienda Ospedaliera San Giovanni Battista, Torino, Italy
2. Clinica di Ematologia Azienda Ospedaliero-Universitaria, Ospedali Riuniti Ancona, Italy
3. Cattedra di Ematologia, Ospedale Ferrarotto, Catania, Italy
New Combination Approaches For Multiple Myeloma
Robert Z. Orlowski, M.D., Ph.D.
The University of Texas M. D. Anderson Cancer Center Houston, Texas, USA
New Proteasome Inhibitors
Shaji Kumar, M.D.
Mayo Clinic, Rochester, MN
Anti-Angiogenic Agents In Multiple Myeloma
S. Vallet, N. Raje
Massachusetts General Hospital Cancer Center and DanaFarber Cancer Institute, Harvard Medical School, Boston, MA
Novel Bone Targeting Agents In Multiple Myeloma (MM)
Martha Q. Lacy MD, Suzanne R. Hayman MD, Morie A. Gertz MD, Angela Dispenzieri MD, Philip R. Greipp MD, Stephen R. Zeldenrust MD PhD, Shaji Kumar MD, John A. Lust MD PhD, Joseph R. Mikhael MD, Vivek Roy MD, Stephen J. Russell MD PhD, Francis Buadi MD, Robert A. Kyle MD, Rafael Fonseca MD, S. Vincent Rajkumar MD, Keith Stewart MD, P. Leif Bergsagel MD, Sumithra J. Mandrekar Ph.D., Jacob B. Allred MS., Kristina Laumann, Melanie Thompson
Mayo Clinic, Rochester, MN, Mayo Clinic, Scottsdale, AZ, Mayo Clinic, Jacksonville, FL
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone (Pom/Dex) As Therapy For Relapsed Multiple Myeloma
Transplant
Muzaffar H. Qazilbash MD - mqazilba@mdanderson.org, Sergio A. Giralt MD
Department of Stem Cell Transplantation and Cellular Therapy, University of Texas-MD, Anderson Cancer Center.
1515 Holcombe Boulevard 423, Houston, TX, 77030
Current Status And Future Directions Of HCT In Myeloma: Moving Beyond High Dose Melphalan
Donna M. Weber, MD
M.D. Anderson Cancer Center, Houston, TX USA
Timing Of Stem Cell Transplant In The Era Of Novel Agents
Michele Cavo, Elena Zamagni, Paola Tacchetti, Michela Ceccolini, Nicoletta Testoni, Carolina Terragna, Annamaria Brioli, Caterina Pallotti, Lucia Pantani, Giulia Marzocchi, Sandra Durante, Alessandro Petrucci, Patrizia Tosi, Michele Baccarani
“Seragnoli” Institute of Hematology and Medical Oncology, Bologna University School of Medicine, Italy
Single Or Double Autologous Stem-Cell Transplantation Before And After The Era Of Novel Agents
Bart Barlogie, Elias Anaissie, Frits van Rhee, John Crowley, John Shaughnessy Jr
Myeloma Institute for Research and Therapy, university of Arkansas for Medical Sciences, Little Rock, AR, USA;
Cancer Research and Biostatistics, Seattle, WA, USA
Curing Multiple Myeloma – Lessons From Total Therapy Protocols
William Bensinger MD, Marcello Rotta, David Maloney
University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA
Allogeneic Stem Cell Transplantation For Multiple Myeloma: Maxi, Mini Or In Between
Thierry Facon, M
Lille University Hospital, France
Post-Transplantation Maintenance In Patients With Multiple Myeloma
Consensus Panel
John Crowley
Cancer Research And Biostatistics
Statistical Issues In The Design And Analysis Of Clinical Studies In Myeloma
Guidelines for Standard Investigative Workup  »    PDF - 72 kB

Meletios A. Dimopoulos, Robert A. Kyle, Sundar Jagannath
on behalf of the International Workshop Panel 3
New IMiD Therapy  »    PDF - 314 kB

Martha Q Lacy, MD
Mayo Clinic
Consensus Panel 2 - Risk Stratification  »    PDF - 139 kB
New combinations for MM  »    PDF - 180 kB

Antonio Palumbo
Div. Hematology, University of Torino, I, EU
Novel Bone Targeting Agents in Myeloma  »    PDF - 1.345 kB

Noopur Raje, MD
Center for Multiple Myeloma MGH Cancer Center
Guidelines for the Uniform Reporting of Clinical Trials: Report of the 2008 International Myeloma Workshop Consensus Panel I  »    PDF - 110 kB

S. Vincent Rajkumar, Jesus San Miguel, Jean Luc Harousseau
on behalf of the International Myeloma Workshop Consensus Panel I


Novel combination therapies for the treatment of relapsed/refractory Multiple Myeloma: Current Phase I/II combinations  »    PDF - 1.570 kB

Paul Richardson, Kenneth C. Anderson, Robert Schlossman, Irene Ghobrial, Constantine Mitsiades, Dharminder Chauhan, Teru Hideshima, Noopur Raje, Nikhil Munshi, Jacob Laubach
Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA





Bearbetat av: Med. dr Artur Jurczyszyn

Krakow, ‏6 mars 2009



Konto i polska zloty  :  06 1440 1127 0000 0000 0835 9709